Clinical trial · Interventional
Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial
UPRISE (Urine Prostate Screening Integrated With MRI for Prostate Cancer Early Detection)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This clinical trial tests how well a urine prostate cancer screening test, My Prostate Score 2 (MPS2), integrated with magnetic resonance imaging (MRI) works for early detection of prostate cancer. MPS2 is an investigational urine-based test designed to help identify the likelihood of having aggressive prostate cancer. MPS2 testing works by measuring specific early detection biomarkers that include genetic information. This next-generation test aims to address a major challenge in prostate cancer care-detecting only the cancers that truly need treatment. Results may lead to paradigm shifts in early detection algorithms and reduce reliance on MRI and biopsy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Carcinoma | Prostate Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biopsy Procedure | Procedure | — | UNRESOLVED |
| Diagnostic Procedure | Device | — | UNRESOLVED |
| Electronic Health Record Review | Other | — | UNRESOLVED |
| Magnetic Resonance Imaging | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Arm I (MPS2)
- description
- Patients undergo urine sample collection for MPS2 testing. Patients' treating physicians review and utilize the results of the MPS2 test to determine if patients undergo SOC MRI and/or biopsy.
- interventionNames
- Procedure: Biopsy Procedure
- Device: Diagnostic Procedure
- Other: Electronic Health Record Review
- Procedure: Magnetic Resonance Imaging
- type
- ACTIVE_COMPARATOR
- label
- Arm II (MPS2)
- description
- Patients undergo urine sample collection for MPS2 testing. Patients' treating physicians do NOT review or utilize results of the MPS2 test to determine if patients undergo a biopsy after SOC MRI.
- interventionNames
- Procedure: Biopsy Procedure
- Device: Diagnostic Procedure
- Other: Electronic Health Record Review
- Procedure: Magnetic Resonance Imaging
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 50 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Males aged 50-75 * PSA 3-20 ng/ml within the previous 3 months * Fit to undergo all procedures listed in protocol per treating physician's discretion * No prostate biopsy in the past 4 years * No prostate MRI in the past 2 years * Able to provide written informed consent Exclusion Criteria: * Prior diagnosis of prostate cancer * Contraindication to MRI (e.g. claustrophobia, pacemaker) * Contraindication to prostate biopsy * Previous hip replacement surgery, metallic hip replacement or extensive pelvic orthopaedic metal work
References
Publications (0)
Data not yet available